HRA Pharma - Company & Market Research Reports

HRA Pharma is a consumer healthcare company that develops treatments in the areas of women’s health and endocrinology. Founded in 1998, HRA is leading the European Emergency Hormonal Contraception Market. The company's women’s health products include ellaOne, Clareva Gel, Cicatridine, Lysodren and Mona Lisa. HRA has 8 products in their portfolio and are marketed in 90 countries worldwide. It has 7 European subsidiaries covering 11 countries, with over 180 employees. It’s headquartered in Paris, France.


Ovarian Cancer - Pipeline Review, H2 2017 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H2 2017

  • Report
  • 2232 Pages
From
Ovarian Cancer - Pipeline Review, H1 2017 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H1 2017

  • Report
  • 2027 Pages
From
Pituitary ACTH Hypersecretion (Cushing Disease) Global Clinical Trials Review, H1, 2016 - Product Thumbnail Image

Pituitary ACTH Hypersecretion (Cushing Disease) Global Clinical Trials Review, H1, 2016

  • Clinical Trials
  • 71 Pages
From
Laboratoire HRA Pharma Company Profile - Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis - Product Thumbnail Image

Laboratoire HRA Pharma Company Profile - Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

  • Company Profile
  • 30 Pages
From
HRA Pharma, SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report - Product Thumbnail Image

HRA Pharma, SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • Mergers and Acquisitions Profiles
  • 50 Pages
From
  • 5 Results (Page 1 of 1)
Loading Indicator
adroll